The estimated Net Worth of David E. Goel is at least $125 Миллион dollars as of 28 January 2014. Mr. Goel owns over 1,000,000 units of Adaptive Biotechnologies stock worth over $2,007,415 and over the last 13 years he sold ADPT stock worth over $123,309,489. In addition, he makes $20,000 as Independent Director at Adaptive Biotechnologies.
Sign up
Mr. Goel ADPT stock SEC Form 4 insiders trading
David has made over 6 trades of the Adaptive Biotechnologies stock since 2014, according to the Form 4 filled with the SEC. Most recently he sold 466,176 units of ADPT stock worth $13,463,163 on 14 May 2014.
The largest trade he's ever made was selling 1,000,000 units of Adaptive Biotechnologies stock on 28 January 2014 worth over $27,640,000. On average, David trades about 146,618 units every 4 days since 2012. As of 28 January 2014 he still owns at least 457,270 units of Adaptive Biotechnologies stock.
You can see the complete history of Mr. Goel stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
David Goel biography
David E. Goel serves as Independent Director of the Company. Mr. Goel is Co-Founder and sole Managing General Partner of Matrix Capital Management Company, LP, an investment fund focused on technology and life sciences. Mr. Goel serves as a director on several private company boards and previously served as a director of Popular, Inc., a public financial services company. He is a member of the Board of Trustees of The Winsor School and the Museum of Fine Arts in Boston, Massachusetts. Mr. Goel holds a BA, magna cum laude, from Harvard University.
What is the salary of David Goel?
As the Independent Director of Adaptive Biotechnologies, the total compensation of David Goel at Adaptive Biotechnologies is $20,000. There are 15 executives at Adaptive Biotechnologies getting paid more, with Lance Baldo having the highest compensation of $3,707,390.
How old is David Goel?
David Goel is 49, he's been the Independent Director of Adaptive Biotechnologies since 2016. There are 12 older and 11 younger executives at Adaptive Biotechnologies. The oldest executive at Adaptive Biotechnologies Corporation is Peter Neupert, 64, who is the Lead Independent Director.
What's David Goel's mailing address?
David's mailing address filed with the SEC is C/O MATRIX CAPITAL MANAGEMENT CO., LP, 1000 WINTER STREET, SUITE 4500, WALTHAM, MA, 02451.
Insiders trading at Adaptive Biotechnologies
Over the last 5 years, insiders at Adaptive Biotechnologies have traded over $685,617,014 worth of Adaptive Biotechnologies stock. The most active insiders traders include Global Investors Lp Viking ..., Global Performance Llc Viki... и Kevin T Conroy. On average, Adaptive Biotechnologies executives and independent directors trade stock every 6 days with the average trade being worth of $368,167. The most recent stock trade was executed by Stacy L Taylor on 22 August 2024, trading 26,922 units of ADPT stock currently worth $121,149.
What does Adaptive Biotechnologies do?
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ research service and kit that is used to answer translational research questions, as well as to discover new prognostic and diagnostic signals; and T-Detect COVID for the confirmation of past COVID-19 infection. It also provides clonoSEQ diagnostic tests, which include immunosequencing services for use in the detection and monitoring of minimal residual disease in patients with select blood cancers; and immunoSEQ T-MAP COVID for vaccine developers and researchers to measure the T-cell immune response to vaccines. In addition, the company offers a pipeline of clinical products and services that are used for the diagnosing, monitoring, and treatment of diseases, such as cancer, autoimmune conditions, and infectious diseases. It serves the life sciences research, clinical diagnostics, and drug discovery customers. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. It also has a research collaboration with Curebase, Inc. to enhance patient participation in clinical studies. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.
What does Adaptive Biotechnologies's logo look like?
Complete history of Mr. Goel stock trades at Popular, Popular Capital Trust II, Popular Capital Trust I и Adaptive Biotechnologies
Adaptive Biotechnologies executives and stock owners
Adaptive Biotechnologies executives and other stock owners filed with the SEC include:
-
Lance Baldo,
Chief Medical Officer -
Chad Robins,
Executive Chairman, Chief Executive Officer, Co-Founder -
Harlan Robins,
Co-Founder, Chief Scientific Officer -
Julie Rubinstein,
President -
Chad M. Robins M.B.A, M.B.A.,
Co-Founder, CEO & Chairman -
Michelle Griffin,
Independent Director -
Kevin Conroy,
Independent Director -
Dr. Harlan S. Robins Ph.D.,
Co-Founder & Chief Scientific Officer -
Julie Rubinstein,
Pres -
Chad M. Cohen CPA,
Chief Financial Officer -
Dr. Mark Adams,
COO & CTO -
Peter Neupert,
Lead Independent Director -
Eric Dobmeier,
Independent Director -
Michael Pellini,
Independent Director -
Robert Hershberg,
Independent Director -
David Goel,
Independent Director -
Sean Nolan,
Chief Technical Officer -
Mark Adams,
Chief Technical Officer -
Charles Snag,
Senior Vice President - Clinical Diagnostics -
Jyoti Palaniappan,
Senior Vice President - Clinical Diagnostics immunoSEQ Dx -
Nancy Hill,
Senior Vice President - Operations -
Sharon Benzeno,
Senior Vice President - Drug Recovery -
Stacy Taylor,
Senior Vice President, General Counsel -
Francis Lo,
Chief People Officer -
Chad Cohen,
Chief Financial Officer -
Francis T. Lo,
Chief People Officer -
Stacy L. Taylor,
Sr. VP & Gen. Counsel -
Karina Calzadilla,
VP of Investor Relations -
Kyle Piskel,
Principal Accounting Officer -
Christopher Carlson Ph.D.,
Founder -
Charles Sang,
SVP, External Affairs -
Global Investors Lpviking G...,
-
Andris A Zoltners,
Director -
David E.Matrix Capital Mana...,
-
Global Performance Llc Viki...,
-
Susan Bobulsky,
Chief Commercial Officer, MRD -
Katey Einterz Owen,
Director -
Leslie Trigg,
Director -
Henning Thorsen,
SVP, Commercial Operations -
Kyle Piskel,
Chief Financial Officer -
Nitin Sood,
Chief Commercial Officer, MRD -
Tycho Peterson,
Chief Financial Officer